Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;28(2):153-6.
doi: 10.1007/s00296-007-0399-1. Epub 2007 Jul 20.

Safety and Efficacy of Once-Weekly Application of Etanercept in Children With Juvenile Idiopathic Arthritis

Affiliations

Safety and Efficacy of Once-Weekly Application of Etanercept in Children With Juvenile Idiopathic Arthritis

Jasmin B Kuemmerle-Deschner et al. Rheumatol Int. .

Abstract

Etanercept-a recombinant TNF receptor fusion protein-has been approved for the treatment of resistant polyarticular juvenile idiopathic arthritis. In children with JIA, 0.4 mg/kg is given subcutaneously twice weekly. In adult patients efficacy and safety of etanercept, 25 mg twice weekly was comparable to 50 mg once weekly. In the German paediatric Etanercept registry six patients with JIA were identified, who received Etanercept once weekly primarily and six patients who received Etanercept initially twice weekly and later once weekly with increased dose per injection. In both groups, treatment was efficacious and well tolerated. In patients switching from twice to once weekly administration, there was no loss of efficacy and no increase in toxicity. At last observation 10/12 patients achieved an ACR-JRA 30 and 8/12 achieved an ACR-JRA70 response. These data indicate that once weekly application of etanercept is safe and efficacous in children.

Comment in

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. Arthritis Rheum. 1997 Jul;40(7):1202-9 - PubMed
    1. Lancet. 1998 Mar 28;351(9107):969-73 - PubMed
    1. Rheum Dis Clin North Am. 1991 Nov;17 (4):891-905 - PubMed
    1. J Rheumatol. 1998 Oct;25(10):1991-4 - PubMed
    1. N Engl J Med. 2000 Mar 16;342(11):763-9 - PubMed

MeSH terms

LinkOut - more resources

Feedback